Charles Chiang Chow

Array ( [id] => 16512876 [patent_doc_number] => 20200392134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => METHOD FOR PURIFYING 2-[[2-[[[3-(4-CHLOROPHENYL)-8-METHYL-8-AZABICYCLO-[3.2.1]-OCT-2-YL]METHYL](2-MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOL-[1R-(EXO-EXO)]TRIHYDROCHLORIDE [patent_app_type] => utility [patent_app_number] => 15/930275 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16589244 [patent_doc_number] => 10898486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Crystal form of orexin receptor antagonist compound, and preparation method and application thereof [patent_app_type] => utility [patent_app_number] => 16/864153 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 8647 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16252078 [patent_doc_number] => 20200261452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/864148 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236738 [patent_doc_number] => 20200253972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/864020 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206428 [patent_doc_number] => 20200239418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => HETEROCYCLIC COMPOUND [patent_app_type] => utility [patent_app_number] => 16/847761 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421829 [patent_doc_number] => 20200347027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => CRYSTALLINE FORMS OF LENALIDOMIDE [patent_app_type] => utility [patent_app_number] => 16/832112 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16832112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343465 [patent_doc_number] => 20200308115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/831370 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16831370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16572877 [patent_doc_number] => 10894790 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Production method of thiazole derivative [patent_app_type] => utility [patent_app_number] => 16/822626 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9270 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156375 [patent_doc_number] => 20200216420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => HISTONE DEMETHYLASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/819875 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16819875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16832081 [patent_doc_number] => 11008321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Crystalline form of an avibactam derivative [patent_app_type] => utility [patent_app_number] => 16/813930 [patent_app_country] => US [patent_app_date] => 2020-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 18462 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770821 [patent_doc_number] => 10981909 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide [patent_app_type] => utility [patent_app_number] => 16/813021 [patent_app_country] => US [patent_app_date] => 2020-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 58 [patent_no_of_words] => 45642 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 288 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17134782 [patent_doc_number] => 11136328 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists [patent_app_type] => utility [patent_app_number] => 16/810258 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 31 [patent_no_of_words] => 49282 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16642039 [patent_doc_number] => 10919873 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/807053 [patent_app_country] => US [patent_app_date] => 2020-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6982 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16807053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17435849 [patent_doc_number] => 11261161 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-01 [patent_title] => Processes for preparing ASK1 inhibitors [patent_app_type] => utility [patent_app_number] => 16/795329 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 26614 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 268 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012553 [patent_doc_number] => 20200181119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => (S)-N-(3-6-ISOPROPOXYPYRIDIN-3-3YL)-1H-INDAZOL-5-YL)-1-(2-(4-4(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H-YL)-2-OXOETHYL)-3(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS [patent_app_type] => utility [patent_app_number] => 16/789123 [patent_app_country] => US [patent_app_date] => 2020-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236590 [patent_doc_number] => 11180461 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Triazoles as Kv3 inhibitors [patent_app_type] => utility [patent_app_number] => 16/785083 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33730 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16785083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222644 [patent_doc_number] => 20200247760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => Compounds, Compositions and Methods for Treatment of Myopia [patent_app_type] => utility [patent_app_number] => 16/779188 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16779188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238161 [patent_doc_number] => 20200255395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/747327 [patent_app_country] => US [patent_app_date] => 2020-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16747327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17134759 [patent_doc_number] => 11136305 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Nicotine salts, co-crystals, and salt co-crystal complexes [patent_app_type] => utility [patent_app_number] => 16/739427 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 25 [patent_no_of_words] => 25577 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16739427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16492324 [patent_doc_number] => 10858348 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-08 [patent_title] => Salt forms of 4-cyano-N-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-Tetr amethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboximide [patent_app_type] => utility [patent_app_number] => 16/737273 [patent_app_country] => US [patent_app_date] => 2020-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 7466 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16737273 [rel_patent_id] =>[rel_patent_doc_number] =>)